Dizziness

Human medicines European public assessment report (EPAR): Lyrica, pregabalin, Date of authorisation: 05/07/2004, Revision: 62, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Patient, Medical Subject Headings, Marketing, European Commission, Neuropathic pain, INN, Tetraplegia, Allergy, ATC, Pain, Capsule, International, European, Spinal cord, Language, Brain, Somnolence, Shingles, Diabetes, Anxiety disorder, Nerve, Dizziness, Anxiety, Anticonvulsant, Water, GAD, Nervous, Peripheral neuropathy, Diabetic neuropathy, Select, Committee, Anatomy, Medicine, Chronic pain, Seizure, IIA, CHMP, Medical device

Human medicines European public assessment report (EPAR): Lyrica, pregabalin, Date of authorisation: 05/07/2004, Revision: 62, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Lyrica, pregabalin, Date of authorisation: 05/07/2004, Revision: 62, Status: Authorised

Human medicines European public assessment report (EPAR): Pregabalin Pfizer, pregabalin, Date of authorisation: 10/04/2014, Revision: 30, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Patient, Medical Subject Headings, Marketing, Pfizer, European Commission, Agency, Neuropathic pain, INN, ATC, Pain, Capsule, International, European, Spinal cord, Diabetes, Language, Butyric acid, Brain, Somnolence, Shingles, Anxiety disorder, Nerve, Dizziness, Anxiety, Water, GAD, Nervous, CHMP, Peripheral neuropathy, Select, Risk management, Anatomy, Medicine, Chronic pain, Seizure, IIA, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Pregabalin Pfizer, pregabalin, Date of authorisation: 10/04/2014, Revision: 30, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Pregabalin Pfizer, pregabalin, Date of authorisation: 10/04/2014, Revision: 30, Status: Authorised

Human medicines European public assessment report (EPAR): Tysabri, natalizumab, Date of authorisation: 27/06/2006, Revision: 42, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Patient, Medical Subject Headings, Marketing, MRI, INN, Risk, Interferon beta-1a, Immune system, Fatigue, Infection, Registry, ATC, Antibody, Gadolinium, Disability, Multiple sclerosis, International, Attack, Spinal cord, Disease, Common, PML, Nose, Headache, Nausea, Brain, Language, Urinary tract infection, Inflammation, Cancer, Nerve, Dizziness, Skin cancer, Allergy, DMT, Death, European Medicines Agency, Nervous system, Select, Carcinoma, Safety, Encephalitis, Anatomy, Arthralgia, Sclerosis, IIA, Magnetic resonance imaging, Medical device

Human medicines European public assessment report (EPAR): Tysabri, natalizumab, Date of authorisation: 27/06/2006, Revision: 42, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Tysabri, natalizumab, Date of authorisation: 27/06/2006, Revision: 42, Status: Authorised

Human medicines European public assessment report (EPAR): Norvir, ritonavir, Date of authorisation: 25/08/1996, Revision: 70, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Liver, Medical Subject Headings, Peripheral neuropathy, Diarrhea, Marketing, Zidovudine, European Commission, Protease, Pharyngitis, INN, Immune system, Heartburn, HIV/AIDS, Fatigue, Saquinavir, Darunavir, ATC, Depression, Itch, Ritonavir, AIDS, International, Capsule, Cough, European, Headache, Disease, CD4, Ageing, Body surface area, Blood, Sore throat, Nausea, Rash, Language, Mouth, Abdominal pain, Dizziness, Flushing, Infection, Food, Indigestion, HIV, Tablet, Chronic pain, Reproduction, Back pain, Select, Committee, Patient, Dysgeusia, Risk management, Anatomy, Medicine, Paresthesia, Vomiting, IIA, Lopinavir, CHMP, Viral load, Vaccine

Human medicines European public assessment report (EPAR): Norvir, ritonavir, Date of authorisation: 25/08/1996, Revision: 70, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Norvir, ritonavir, Date of authorisation: 25/08/1996, Revision: 70, Status: Authorised

Human medicines European public assessment report (EPAR): Xolair, omalizumab, Date of authorisation: 25/10/2005, Revision: 49, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Atmosphere, Patient, Medical Subject Headings, Quality of life, Fluticasone, Marketing, Sinusitis, Agency, INN, Fever, Lower respiratory tract infection, Immunoglobulin E, Allergy, ATC, Chronic pain, Pain, International, Headache, Ageing, Nose, Blood, Language, MITES, Pharyngitis, Swelling, Inflammation, Dizziness, Red, European Medicines Agency, Polyp (medicine), Select, Overalls, Anatomy, Arthralgia, IIA, Pollen, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Xolair, omalizumab, Date of authorisation: 25/10/2005, Revision: 49, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Xolair, omalizumab, Date of authorisation: 25/10/2005, Revision: 49, Status: Authorised

Human medicines European public assessment report (EPAR): Evkeeza, evinacumab, Date of authorisation: 17/06/2021, Revision: 3, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Medical Subject Headings, Marketing, LDL, Cholesterol, Artery, Anaphylaxis, Agency, INN, Adolescence, Atherosclerosis, Collection, ATC, Apolipoprotein, International, Diet, Ill, Disease, Ageing, Nose, Blood, Nausea, Language, Heart, Inflammation, Dizziness, Allergy, European Medicines Agency, Back pain, Enzyme, Select, Human, Patient, Safety, Cardiovascular disease, Fats, Anatomy, Medicine, ANGPTL3, IIA, Medical device

Human medicines European public assessment report (EPAR): Evkeeza, evinacumab, Date of authorisation: 17/06/2021, Revision: 3, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Evkeeza, evinacumab, Date of authorisation: 17/06/2021, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Mepact, mifamurtide, Date of authorisation: 06/03/2009, Revision: 20, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Marketing, Plasma protein binding, Constipation, INN, Risk, Hypotension, Hypertension, Fatigue, Nausea, Cancer, Inflammation, Tachypnea, Back pain, Chest pain, Diagnosis, Anatomy, Cough, IIA, CHMP, Chills, Diarrhea, Fever, ATC, Pain, European, Disease, Ageing, Weakness, Nonsteroidal anti-inflammatory drug, Human, Tachycardia, Anemia, Arthralgia, Medical Subject Headings, European Commission, Immune system, International, Language, Somatic symptom disorder, Myalgia, Dizziness, Monocyte, Select, Patient, Medicine, Hyperhidrosis, Vomiting, Allergy, Headache, Mifamurtide, Macrophage, Abdominal pain, Hypothermia, Chronic pain, Safety, Committee, Periodic breathing, Medical device

Human medicines European public assessment report (EPAR): Mepact, mifamurtide, Date of authorisation: 06/03/2009, Revision: 20, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Mepact, mifamurtide, Date of authorisation: 06/03/2009, Revision: 20, Status: Authorised

Human medicines European public assessment report (EPAR): Bimervax, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 30/03/2023, Revision: 3, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
People, Marketing, Immunodeficiency, INN, Risk, Sensation, Messenger, Delta, Nausea, RMP, Vaccination, Heart, Inflammation, Back pain, SARS, Hardness, Bruise, Anatomy, IIA, Odynophagia, Hypoesthesia, Skin, Chills, Diarrhea, Fever, Fatigue, ATC, Pain, Ageing, Pregnancy, Somnolence, Arthralgia, Medical Subject Headings, Agency, Immune system, Allergy, Antibody, EMA, International, Language, Pfizer–BioNTech COVID-19 vaccine, Dizziness, Select, Patient, Vomiting, Erythema, Pericarditis, Lymph, System, Vaccine, Weakness, Headache, Abdominal pain, Swelling, Hypersensitivity, Temperature, COVID-19, SARS-CoV-2, Myalgia, Paresthesia, Rash

Human medicines European public assessment report (EPAR): Bimervax, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 30/03/2023, Revision: 3, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Bimervax, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 30/03/2023, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Jakavi, ruxolitinib, Date of authorisation: 23/08/2012, Revision: 29, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Janus, Liver, Marketing, PV, INN, Hypertension, Graft-versus-host disease, Polycythemia, Hydroxycarbamide, Infection, Transplant, Splenomegaly, Bruise, Polycythemia vera, Bacteria, Anatomy, IIA, Spleen, Fever, Hypercholesterolemia, Primary myelofibrosis, ATC, Bleeding, Disease, Ageing, JAK, Neutrophil, Blood, System, Disorder, Weight gain, Enzyme, Safety, Anemia, Sepsis, Medical Subject Headings, Agency, B cell, International, Bone pain, Neutropenia, Language, Mouth, Dizziness, Thrombocytopenia, Pancreatic serous cystadenoma, Hypertriglyceridemia, Tablet, Select, Patient, Medicine, Phlebotomy, Hormone, Woman, Weight loss, Headache, Cytomegalovirus, European Medicines Agency, Growth, Janus kinase, Urinary tract infection, Medical device

Human medicines European public assessment report (EPAR): Jakavi, ruxolitinib, Date of authorisation: 23/08/2012, Revision: 29, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Jakavi, ruxolitinib, Date of authorisation: 23/08/2012, Revision: 29, Status: Authorised

Human medicines European public assessment report (EPAR): Spikevax (previously COVID-19 Vaccine Moderna), COVID-19 mRNA vaccine,elasomeran,elasomeran / imelasomeran,elasomeran / davesomeran,andusomeran, Date of authorisation: 06/01/2021, Revision: 41[...]

Retrieved on: 
Tuesday, January 2, 2024
People, Marketing, Immunodeficiency, INN, Risk, Woman, Sensation, COVID 19, Messenger, Nausea, Myocarditis, DNA, Erythema multiforme, Vaccination, Heart, Inflammation, COVID, Obesity, Liver disease, Anatomy, Paresthesia, IIA, Skin, Hypoesthesia, Chills, Diarrhea, COVID-19 vaccine, Fever, Fatigue, Infection, ATC, Pain, Palsy, Disease, Ageing, Profile, Omicron, Allergy, Pregnancy, HIV, Thigh, Safety, Somnolence, RNA, Medical Subject Headings, Group, Immune system, HIV/AIDS, Antibody, International, Injection, Crying, Language, Dizziness, Select, Patient, Vomiting, Pericarditis, Anaphylaxis, Arm, System, Vaccine, Diabetes, Headache, Abdominal pain, Clinical trial, Swelling, Hypersensitivity, Irritability, Temperature, COVID-19, European Medicines Agency, Face, Cell, Miscarriage, Rash

Human medicines European public assessment report (EPAR): Spikevax (previously COVID-19 Vaccine Moderna), COVID-19 mRNA vaccine,elasomeran,elasomeran / imelasomeran,elasomeran / davesomeran,andusomeran, Date of authorisation: 06/01/2021, Revision: 41, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Spikevax (previously COVID-19 Vaccine Moderna), COVID-19 mRNA vaccine,elasomeran,elasomeran / imelasomeran,elasomeran / davesomeran,andusomeran, Date of authorisation: 06/01/2021, Revision: 41, Status: Authorised